Last updated: July 19, 2026
BIOMARIN v. TEVA (2:21-cv-15392): Litigation Summary, Claims at Issue, and Practical Risk Analysis
Executive summary: The BIOMARIN PHARMACEUTICAL INC. v. TEVA PHARMACEUTICALS, INC. case docketed as 2:21-cv-15392 is a Hatch-Waxman patent infringement dispute tied to Teva’s abbreviated regulatory pathway and Biomarins asserted patents. The litigation posture, asserted patent set, and relief sought determine (i) whether Teva’s ANDA is enjoined and (ii) which manufacturing and formulation design-arounds are legally safe. Without the underlying complaint, claim chart, and Orange Book patent listing tied to the asserted FDA product, a complete, accurate litigation summary cannot be produced.
What is BIOMARIN PHARMACEUTICAL INC. v. TEVA PHARMACEUTICALS, INC. 2:21-cv-15392 about?
Answer (high level): It is a patent infringement action filed by BioMarin against Teva in the ANDA/Hatch-Waxman context, typically alleging infringement of listed Orange Book patents and seeking relief to prevent Teva’s generic launch during the patent-protected period.
What patents are usually asserted in BioMarin v. Teva ANDA litigation?
Typical categories (contextual):
- Formulation and composition patents for drug product and excipients
- Method-of-use or dosing regimen patents
- Manufacturing method patents
- Device or delivery system patents (if applicable)
- Polymorph/solid-state form patents (for small-molecule products)
Which FDA product is implicated in 2:21-cv-15392?
Answer: Cannot be determined from the provided docket identifier alone.
What patents protect BioMarin products involved in teva ANDA challenges?
Answer (high level): BioMarin patent estates in Hatch-Waxman cases commonly combine Orange Book-listed composition/formulation claims with one or more method-of-use or manufacturing process claims.
How do BioMarin patent estates typically create entry barriers?
- Composition/formulation protections can block generic product design-around if claim scope covers excipient levels, solid-state characteristics, or specific manufacturing steps.
- Method-of-use claims can create “use carve-outs” that are difficult to operationalize if the generic label mirrors the reference regimen.
- Manufacturing method claims can force process changes that can be costly and slow.
When does exclusivity expire for the BioMarin product at issue, and how does that affect infringement leverage?
Answer: Cannot be determined from the provided docket number alone. Exclusivity outcomes depend on:
- FDA exclusivity type (e.g., NCE, BLA/biologic exclusivity, pediatric exclusivity, 505(b)(2) exclusivity)
- Orange Book listed patents with grant and expiration schedules
- Settlement and consent judgment terms (if any)
What is the Orange Book status of the BioMarin drug at issue in 2:21-cv-15392?
Answer: Cannot be determined from the provided information. Orange Book status requires:
- The reference listed drug (RLD)
- The specific patents asserted in the case
- Patent numbers and expiration dates tied to the RLD
What is the procedural posture in 2:21-cv-15392 (motions, scheduling, claim construction)?
Answer: Cannot be produced accurately without docket entries, court orders, and the case’s current status.
What matters most in BioMarin v. Teva timing
- Whether Teva filed a Paragraph IV certification and what patents were certified as invalid or not infringed
- Whether the case is resolved by dismissal/settlement before Markman
- Whether the court stayed litigation pending FDA decisions
How strong is the patent estate for BioMarin versus Teva’s generic risk profile?
Answer: Cannot be quantified from the provided docket number alone.
What drives strength in this type of case
- Claim breadth versus known prior art and obviousness
- Written description and enablement support
- Prosecution history estoppel or disclaimer
- Infringement proof including product characterization (e.g., particle size, polymorph, excipient profile)
- Willfulness allegations and damages posture
What defenses does Teva typically raise in BioMarin Hatch-Waxman litigation?
Answer (typical):
- Noninfringement (no literal infringement and no doctrine of equivalents)
- Invalidity under 35 USC 102/103/112 and lack of written description or indefiniteness
- Statutory limitations (e.g., non-commercial use and carve-outs)
- Inequitable conduct (if supported by the record)
Do Teva’s design-arounds usually reduce infringement exposure?
Answer (typical): They can, but only if the asserted claims do not read onto the redesigned formulation or process. Without the asserted claim set and Teva’s product design facts, no reliable analysis is possible.
What generic entry risks exist for Teva if BioMarin’s patents are upheld?
Answer: Entry risk depends on whether the patents are found valid and infringed, and whether the court enters an injunction covering the specific teva product and relevant label or method-of-use.
If patents are invalidated, what launch path opens?
Answer (typical):
- Teva may be able to launch earlier than the patent expiry date if the asserted patents are invalid or not infringed
- Remaining unasserted Orange Book patents could still block launch
What patent litigation affects BioMarin product commercialization in the generic pipeline?
Answer: BioMarin patent litigation affects:
- Launch timing of first ANDA filers
- Settlement positioning of subsequent challengers
- Pricing leverage for BioMarin and contracting dynamics
How do settlements usually change the competitive landscape?
Answer (typical): Settlements often include:
- A covenant not to sue during a defined period
- Design-around limitations
- “Allowed” launch date tied to patent expiry
- Dismissal with or without stipulated earlier entry
Key Takeaways
- 2:21-cv-15392 is a Hatch-Waxman-style BioMarin vs. Teva patent infringement dispute, but the asserted patents, FDA product, and current procedural status are not provided.
- A complete litigation summary and analysis (claims at issue, legal theories, posture, likely outcomes, and market entry risk) cannot be accurately generated from the docket number alone.
FAQs
- What does a Paragraph IV certification mean in BioMarin v. Teva cases?
- How do method-of-use patents affect generic labeling carve-outs in Hatch-Waxman litigation?
- What evidence typically proves infringement for formulation and solid-state claims in generic disputes?
- How do settlement agreements usually structure “design-around” boundaries for ANDA filers?
- What is the typical impact of an injunction on a generic’s launch timeline?
References
- Not available from the information provided.
